Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Empagliflozin Versus Sitagliptin Therapy for Improvement of Myocardial Perfusion Reserve in Diabetic Patients With Coronary Artery disease_ELITE Trial

NCT03208465 is registered in ClinicalTrials.gov with CHEOL WHAN LEE, M.D., Ph.D as lead sponsor.

NCT NCT03208465
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03208465 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Empagliflozin Versus Sitagliptin Therapy for Improvement of Myocardial Perfusion Reserve in Diabetic Patients With Coronary Artery disease_ELITE Trial
Lead sponsor
CHEOL WHAN LEE, M.D., Ph.D
Phase
Phase 4
Overall status
Completed
Start date
August 7, 2017
Completion date
August 1, 2019
Enrollment
100 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

coronary disease, diabetes mellitus